At 12 months, tumor-freezing plus hormone therapy had a 97.5% response rate in 40 breast cancer patients.
IceCure Medical (ICCM) presented 12-month clinical data for its ProSense® breast cancer cryoablation system at EUSOBI, showing a 97.5% response rate in 40 patients. The company hosted workshops and scientific sessions, highlighting strong physician engagement and growing interest in the minimally invasive treatment.
How this was made
The 30-second read
Why it matters
The disclosed 97.5% response rate could drive sales growth, improve market perception, and attract further clinical adoption.
Market read
Strong trial results for a niche oncology device may lift ICCM's stock and influence the medical‑device sector.
What to watch
Reimbursement policies and competitive landscape for breast‑cancer treatments could temper upside.
Background
IceCure Medical (Nasdaq: ICCM) develops liquid‑nitrogen cryoablation systems. The ProSense® system is the only FDA‑cleared device for certain breast‑cancer patients.
Ticker impact
IceCure Medical disclosed 12‑month tumor‑free response rate of 97.5% in 40 breast‑cancer patients for its ProSense® cryoablation system.
likely upward pressure as the market prices in the strong efficacy results.
First disclosure of robust 12‑month outcomes; no prior public data on this cohort.
Market effects
May increase interest in minimally invasive oncology devices and boost the broader medical‑device sector.
Potentially strengthens IceCure's position in U.S., European and Asian markets where the device is cleared.
Highlights growing adoption of cryoablation technology worldwide.
Counterpoint
Skeptics may question the small sample size and limited patient population before committing capital.
Key entities
- CompanyIceCure Medical
Developer of the ProSense® cryoablation system.
- OrganizationEUSOBI
European breast imaging society where the data were presented.
